Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000644134 | SCV000765824 | benign | Tuberous sclerosis 2 | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002449026 | SCV002611785 | likely benign | Hereditary cancer-predisposing syndrome | 2023-06-09 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV003128676 | SCV003805893 | likely benign | not provided | 2018-10-11 | criteria provided, single submitter | clinical testing | See Variant Classification Assertion Criteria. |
St. |
RCV000644134 | SCV004171415 | uncertain significance | Tuberous sclerosis 2 | 2023-11-13 | criteria provided, single submitter | clinical testing | The TSC2 c.3240A>C (p.Leu1080Phe) missense change has a maximum subpopulation frequency of 0.00089% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org). The in silico tool REVEL is inconclusive about a pathogenic or benign effect of this variant on protein function, and to our knowledge functional studies have not been performed. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. |
All of Us Research Program, |
RCV004003999 | SCV004817476 | uncertain significance | Tuberous sclerosis syndrome | 2023-11-30 | criteria provided, single submitter | clinical testing | This missense variant replaces leucine with phenylalanine at codon 1080 of the TSC2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 1/250106 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |